|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0005823,
umls-concept:C0008976,
umls-concept:C0014653,
umls-concept:C0020261,
umls-concept:C0032821,
umls-concept:C0034656,
umls-concept:C0043210,
umls-concept:C0232970,
umls-concept:C0857121,
umls-concept:C1280500,
umls-concept:C1636671
|
|
pubmed:issue |
3 Pt 1
|
|
pubmed:dateCreated |
2007-5-9
|
|
pubmed:abstractText |
Drospirenone (DRSP), a spironolactone analog with aldosterone antagonist activity, is a novel progestogen developed for use as hormone therapy in postmenopausal women in combination with 17beta-estradiol (E2). DRSP/E2 lowers blood pressure when used alone in hypertensive postmenopausal women or when administered concomitantly with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. DRSP/E2 has not been studied in combination with the widely prescribed hydrochlorothiazide (HCTZ). We investigated the effects of 3 mg DRSP/1 mg E2 versus placebo on blood pressure and potassium balance when added to existing therapy with 25 mg HCTZ in postmenopausal women with established stage I hypertension.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1072-3714
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
14
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
408-14
|
|
pubmed:meshHeading |
pubmed-meshheading:17224857-Aged,
pubmed-meshheading:17224857-Aldosterone Antagonists,
pubmed-meshheading:17224857-Androstenes,
pubmed-meshheading:17224857-Antihypertensive Agents,
pubmed-meshheading:17224857-Blood Pressure,
pubmed-meshheading:17224857-Blood Pressure Determination,
pubmed-meshheading:17224857-Dose-Response Relationship, Drug,
pubmed-meshheading:17224857-Double-Blind Method,
pubmed-meshheading:17224857-Drug Combinations,
pubmed-meshheading:17224857-Estrogen Replacement Therapy,
pubmed-meshheading:17224857-Female,
pubmed-meshheading:17224857-Humans,
pubmed-meshheading:17224857-Hydrochlorothiazide,
pubmed-meshheading:17224857-Hypertension,
pubmed-meshheading:17224857-Middle Aged,
pubmed-meshheading:17224857-Postmenopause,
pubmed-meshheading:17224857-Potassium,
pubmed-meshheading:17224857-Treatment Outcome
|
|
pubmed:articleTitle |
Randomized, placebo-controlled trial of the effects of drospirenone-estradiol on blood pressure and potassium balance in hypertensive postmenopausal women receiving hydrochlorothiazide.
|
|
pubmed:affiliation |
Division of Clinical Pharmacology and Pharmacokinetics Clinical Research Center, Department of Medicine, Miller School of Medicine, University of Miami, FL 33136, USA. rpreston@med.miami.edu
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Controlled Clinical Trial,
Research Support, Non-U.S. Gov't
|
